AMNEAL Pharmaceuticals announced the approval of their [Substance] abbreviated new drug application, a move that is projected to drive significant cost management for payers by substituting the higher-priced [Brand Name] as the reference product. The ANDA approval is expected to immediately impact the market landscape by redirecting a substantial share of [Brand Name]’s U.S. sales volume.